• Sensorium Therapeutics

  Participated · Series A · Nov 2022

  Sensorium Therapeutics develops brain and mental health treatments derived from natural products and driven by mechanistic neuroscience. Its proprietary SensAI platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience. SensAI has produced three differentiated programs in under three years, led by SNTX-2643, a first-in-class precision serotonin modulator for anxiety. The company recently received FDA clearance of an IND for SNTX-2643, enabling first-in-human dosing beginning in Q3 2025. Sensorium describes SNTX-2643 as re-engineered from a natural product to enable rapid onset, reduce off-target side effects, and avoid sedation versus benzodiazepine-like drugs. Sensorium has built an IP estate extending into the 2040s and has made executive leadership changes concurrent with its clinical advancement. Sensorium Therapeutics is a Boston-based biotechnology company developing nature-inspired psychoactive medicines for mental health. The company leverages medicinal chemistry, neuroscience, and machine learning to discover and optimize compounds. Its initial asset is SENS-01 and it operates the Biodynamic Discovery Platform (BDP), a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as novel therapeutics. Sensorium closed a $30 million Series A financing to advance SENS-01 and further develop the BDP. The company aims to use the proceeds to move those programs forward.

• Delix Therapeutics

  Participated · Series A · Sep 2021

  Delix Therapeutics develops small‑molecule psychoplastogens that rapidly induce structural and functional neural changes in targeted brain areas. Its compounds are inspired by psychedelic compounds but are engineered to preserve efficacy while avoiding hallucinogenic properties and other safety liabilities. The company is advancing multiple candidates through preclinical and clinical development with the goal of bringing FDA‑approved, take‑home medicines to patients. Delix intends to use new funds to grow its drug development program, expand its pipeline and platform, hire additional team members, and pursue strategic opportunities in 2022. The company is led by CEO Mark Rus and is based in Boston, MA. Financially, Delix recently completed a convertible note financing and secured a strategic credit facility to support its programs alongside a prior $70M Series A in September 2021. Delix Therapeutics is a Boston-based preclinical neuroscience company developing non-hallucinatory, neuroplasticity-promoting therapeutics called psychoplastogens to treat mental illness and other brain disorders at scale. Its small-molecule compounds are designed to rapidly induce structural and functional neural changes in targeted brain regions while avoiding the hallucinogenic effects of first-generation psychedelics. Delix's discovery engine has produced nearly 1,000 novel compounds and identified several potential clinical development candidates. Its most advanced, orally bioavailable analogs—profiled in Nature and Cell—seek to preserve long-lasting beneficial neural rewiring without the safety liabilities and access barriers of classic psychedelics. The company raised $70M in a Series A to advance its non-hallucinatory, take-home candidates into clinical trials and to expand its team. DLX-1 and DLX-7, the first two development candidates, are undergoing pre-IND safety and toxicology studies to enable clinical trials in 2022.

• Ksana Health

  Participated · Seed · Jun 2021

  Ksana Health builds mobile therapy software that passively collects data from smartphones (movement, GPS, keystrokes, language patterns, screen time and other sensors) and funnels that information to clinicians through an app and a detailed dashboard. Its current commercial product, the Effortless Assessment Research System (EARS), is used in clinical research and has generated about $900,000 in revenue from trial usage. The company is developing Vira, a consumer-facing product that will give therapists access to a patient’s passive data via a personalized code and enable behavioral nudges; Vira targets users aged 13–30. Vira has not yet launched and has no clinical trials of the full product, though Ksana plans clinical trials and a pilot via Anthem’s Digital Incubator with Beacon Health Options. Ksana was founded by University of Oregon professor Nicholas Allen, employs 12 people, and emphasizes keeping a human therapist “in the loop” rather than relying on fully automated AI systems. The company projects a Vira launch in the first quarter of 2022 and aims to embed the product within practitioner workflows and insurer pilots.

No current team members are available.